MolMed S.p.A._2_

					                             an integrated
                                  strategy
                            to cure cancer




MolMed S.p.A.
Company presentation
2nd Italian Stock Market
Opportunities Conference
Milan, September 17, 2009
                                                                                     Forward-looking statements

This presentation may contain certain forward-looking statements.
Although the Company believes its expectations are based on reasonable assumptions, these
forward-looking statements are subject to numerous risks and uncertainties, including
scientific, business, economic and financial factors, which could cause actual results to differ
materially from those anticipated in the forward-looking statements.
The company assumes no responsibility to update forward-looking statements or adapt them to
future events or developments. This presentation does not constitute an offer or invitation to
subscribe or purchase any securities of MolMed S.p.A.


Declaration by the official Corporate Financial Reporting Manager:
The undersigned herewith attests, pursuant to Article 154-bis, paragraph 2 of the Italian
Consolidated Law on Finance (Legislative Decree 58/1998), that the accounting disclosure
contained in this presentation matches documentary evidence, corporate books, and
accounting records.
Enrico Cappelli, Chief Financial Officer, official Corporate Financial Reporting Manager




MolMed S.p.A. – Italian Stock Market Opportunities Conference, Milan, September 17, 2009                      2
                                                                                           Agenda


      Company overview
      Long-term strategy
      MolMed’s oncology pipeline
      A unique value proposition in cancer therapy
      Milestones
      Financial outlook
      Summary




MolMed S.p.A. – Italian Stock Market Opportunities Conference, Milan, September 17, 2009        3
                                                 Clinical-stage company focused on oncology

    Public company listed on the Milan Stock Exchange (MLM.MI)
    2 anticancer therapeutics in advanced clinical development
    Option right to IP of biomedical research leader San Raffaele Institute
    Access to Asian markets through alliance with Takara Bio Inc. (Japan)
    Experienced management team
    91 full time employees




MolMed S.p.A. – Italian Stock Market Opportunities Conference, Milan, September 17, 2009   4
                        Team combining scientific and industrial expertise (I/II)

                Claudio Bordignon, MD, President and CEO
                Former Scientific Director of the San Raffaele Scientific Institute, and pioneer
                in the clinical validation of several successful cell-based therapies, for both
                genetic and acquired disorders. Among the 22 eminent founding members of
                the Scientific Council of the European Research Council (ERC)
                Marina Del Bue, BSC, MBA, General Manager, Member of the Board
                Over 20 years experience in managing product development in the pharma
                industry, previously at Menarini Group. She led MolMed’s evolution from service
                to product company. Member of the Boards of EuropaBio and VP of Assobiotec

                Enrico Cappelli, BEC, Chief Financial Officer
                14 years experience in positions of increasing responsibility in finance and
                administration management, previously at a Group listed at Borsa Italiana.
                Chartered Accountant and member of the Official Register of Public Auditors

                Holger Neecke, PhD, MBA, Director Business Development
                At MolMed since 2001, he is in charge inter alia of building MolMed’s strategic
                alliances. He closed license agreements with pharma and biotech companies in
                EU, US and Japan

MolMed S.p.A. – Italian Stock Market Opportunities Conference, Milan, September 17, 2009           5
                      Team combining scientific and industrial expertise (II/II)

                Cynthia Giuliani, BA Hons, Director Human Resources
                20 years experience in human resources and compensation related matters, gained in
                multinational and biotech companies such as Roche and Liebert Hiross, and most recently in
                Bioxell
                Daniele Pieraccioli, PhD, European Patent Attorney, Director IP
                30 years experience in pharma and biotech companies, including GlaxoSmithKline and Serono.
                Member of the Board of the European Patent Institute and Board Director of the European
                Association of Patent Attorneys in Industry
                Gian Paolo Rizzardi, MD, Director Research
                15 years experience in research on immunotherapeutic strategies. Working at MolMed, he also
                developed a broad and in-depth experience in tumour homing pepdies and vascular targeting
                agents. Previously at the University of Lausanne
                Raul Ziliotto, BSC, Director Drug Development
                20 years experience in drug development focused on biological and biotech-based drugs.
                Formerly Director of Biological Products Development and responsible for plant validation at
                Pharmacia, Pharmacia-Upjohn, Pfizer and Nerviano Medical Sciences
                Marco Dieci, BSC, Qualified Person, Director Operations
                10 years experience in QC, QA and GMP production of medicinal products, previously at Chiesi
                Farmaceutici SpA e Lameplast SpA

                Antonio Lambiase, MD, Director Clinical Development
                Over 15 years experience at Roche in the areas of oncology and haematology, as medical
                responsible for the clinical development of several novel biotech-based compounds

MolMed S.p.A. – Italian Stock Market Opportunities Conference, Milan, September 17, 2009                       6
                                                                                             Long-term strategy




                                                                                                     Diversified
                                                                                                 pipeline to create
                                                                                    GMP               value for
                                                                             manufacturing of       shareholders
                                         Efficient clinical &
                                                                             cell/gene therapy
                                          pharmaceutical
                                                                                  products
                                            development
            Focus on                       independently
            oncology                      or with partners
           indications
          needing new
             options




                            Industrial project built on a strong science basis

MolMed S.p.A. – Italian Stock Market Opportunities Conference, Milan, September 17, 2009                              7
                                                 Product pipeline: focus on unmet needs in oncology

   Indications targeted by MolMed’s investigational therapies
                                700.000
                                                       Colon-rectum
                                600.000
 Europe, Japan and Australia)
  Incidence (North America,




                                500.000                                                  Lung
                                                                                        (NSCLC)
                                                                                                           No or few treatment options
                                400.000                        NGR-hTNF
                                                               NGR-hTNF                                    approved or in develoment in:
                                                                                                               First/second line
                                300.000
                                                                                                               Third/fourth line
                                                                                         Lung
                                200.000                                                 (SCLC)
                                                                           Leukaemia             Liver
                                100.000
                                                                   Ovary
                                                               Sarcomas1                          Mesothelioma1
                                     0                                             TK
                                                                                   TK
                                          0,00         0,33                 0,67                    1,00
                                                      Mortality / incidence ratio
                                                     Unmet medical need

Source: Globocan 2002; 1Company estimate
MolMed S.p.A. – Italian Stock Market Opportunities Conference, Milan, September 17, 2009                                                   8
                           Efficient development independently or with partners


Molmed has adopted a flexible business strategy:
    Specialised indications (TK): in-house clinical development, production and marketing
    (except in Asia)
    Indications with large market potential (NGR-hTNF): open to partnerships with major
    pharma and biotech companies for full clinical development, production and marketing


                 Pharmaceutical development and manufacturing

                            Clinical-grade                     Industrial                               Avecia Biologics
                                                                                                          Industrialisation of
                                                                                                          NGR-hTNF production
       Research             Preclinical            Clinical             Marketing           Hospital      process
                           development           development            and Sales          (patients)
                                                                                                          Supplier of market-
                                                                                                          compliant product for
                                                                                                          Phase III
HSR - San Raffaele Scientific Institute                               Takara Bio Inc
  Host institution: strategic context for                               Licensee and co-developer of TK for Asia
  healthcare R&D                                                        Conducting Phase I of TK in Japan
  Option right on research in cancer

MolMed S.p.A. – Italian Stock Market Opportunities Conference, Milan, September 17, 2009                                      9
                                                                   In-house GMP manufacturing facility


    Status of pharmaceutical company granted by the Italian Drug
    Agency (AIFA)

    Track record of investigational gene therapies for rare diseases

    Manufacturing of genetically modified patient-specific cells
       •    Production of own cell-based therapeutics
       •    Clinical-grade cell manipulation services

    Clinical-grade lots released by Qualified Person

    Customised project design from preclinical development to
    Phase III

    Regulatory support

      Acknowledged international reputation in GMP activities
                    In cell and gene therapy
MolMed S.p.A. – Italian Stock Market Opportunities Conference, Milan, September 17, 2009             10
                                                                                           MolMed oncology pipeline


Product        Indication (trial code)            Res Precl                                 Phase I   Phase II   Phase III
TK             High-risk leukaemia (TK007, TK008)
               Leukaemia/Japan [by Takara Bio]
NGR-hTNF       Solid tumours [ MTD] (EORTC)
               Solid tumours [low dose] (NGR002)
               Colorectal cancer (NGR006)
 single agent
               Hepatocarcinoma (NGR008)
               Mesothelioma (NGR010)
               Solid tumours [high dose] (NGR013)
               Solid tumours (NGR003)
               Small cell lung cancer (NGR007)
 + doxorubicin
               Ovarian cancer (NGR012)
               Sarcomas
 + Xelox       Colorectal cancer (NGR005)
 + cisplatin   Solid tumours (NGR004)
   cis/gem     Lung cancer/NSCLC (NGR014)
 +
   cis/pem
NGR-IFNγ       Solid tumours
NGR-IL12       Solid tumours
Legenda for clinical trials:       completed         ongoing      planned
MolMed S.p.A. – Italian Stock Market Opportunities Conference, Milan, September 17, 2009                                     11
                                                                                    TK: a cell-based therapy
                                                                     enabling safe and effective haplo-HSCT

    Cell therapy based on genetically engineered donor T cells
    Enables Haematopoietic Stem Cell Transplant (HSCT) from partially compatible donors
    (haplo-HSCT)
    Allows to keep the benefits of add-backs of donor T cells in haplo-HSCT
    In Phase III for high-risk leukaemia adult patients
    Orphan Drug Status in the EU (2003) and in the US (2005)
            Overview of the TK therapy procedure
                                    Donor                             Hospital                                                Graft versus
                                   haemat.                                                                            Infection (GvI) and support
                                  stem cells                                                         TK cells          to stem cells engraftment
                                       Haemat.
                                      stem cells                                                       TK cells
                                                                                                                          Graft versus
                                                   HSC transplant                 TK cell infusion                      Leukaemia (GvL)
                                                      (day 0)                        (day 21)


                    Haploidentical donor
                                                                                                                      Graft versus
                   (from bone marrow or
                                                                                                                  host disease (GvHD)
                      peripheral blood)                                MolMed GMP facility
                                                                    donor T cells transduction,
                                                                     selection and expansion                                    Abrogation by
                                      T cells
                                                                                                                              administration of
                                                                                                                                 Ganciclovir

                                     donor
                                     T cells                 LTR        TK       SV ∆LNGFR    LTR



MolMed S.p.A. – Italian Stock Market Opportunities Conference, Milan, September 17, 2009                                                            12
                                                                     Key results of Phase I/II trial TK007

  TK007 trial data
                                            4 drop-out (no HSCT)


     54 enrolled                           22 no TK cells infusion
                                                                                           6 not immune-reconstituted
                                           28 infused with
                                               TK cells                                    22 immune-reconstituted (IR)
                                                                                                   (>100 CD3+ cells/ml)


                                                                                 TK007
                                                                                                  Historical data
                                                                               IR patients
                         Transplant-related mortality
                                                                                    10%                50%
                         (at 50 months from HSCT)
                         Disease relapse                                            10%               20-30%
                         4-year disease-free survival                               45%               20-30%
                         GvHD occurrence                                            50%
                                                                                                       n.a.
                               control                                             100%


Source: Ciceri, Bonini et al., Lancet Oncol. 2009 May 1;10:489-500
MolMed S.p.A. – Italian Stock Market Opportunities Conference, Milan, September 17, 2009                                  13
                                                                                  TK: summary of clinical trials

    Academic studies: 91 patients treated, proving the safety of gene transfer and
    cell manipulation processes

    Phase I/II trial (TK007) completed – Results published by The Lancet Oncology
    (2009 May;10(5):489-500

    Phase III trial (TK008) started in Italy in 2008
       •   First Phase III trial authorised in Italy for a cell/gene therapy

    Phase I trials in Japan started in October 2008 and April 2009
       •   2 trials in leukaemia patients: receiving allo-HSCT or haplo-HSCT
       •   Conducted by Takara Bio Inc. at the National Cancer Centre in Tokyo




                          TK clinical validation now in Phase III randomised trial



MolMed S.p.A. – Italian Stock Market Opportunities Conference, Milan, September 17, 2009                       14
                                             TK opens the door of bone marrow transplant
                                                                           to all patients

Advantages assessed in Phase II trial (TK007):
    Early and sustained immune-reconstitution
    Reduction of transplant-related mortality
    Protection from relapse
    Prompt control of Graft versus Host Disease
    Safety of the gene transfer and cell manipulation procedures




          Prompt donor availability for all adult patients
              (~ 50%) lacking a fully compatible one




MolMed S.p.A. – Italian Stock Market Opportunities Conference, Milan, September 17, 2009   15
                                       NGR-hTNF: a novel vascular targeting agent with
                                          broad therapeutic potential in solid tumours

   First-in-class vascular targeting agent (VTA)
   Recombinant homotrimeric fusion protein

   Structure of NGR-hTNF (1 subunit)




                                                                                           Human TNF:
                                                                                             Binds to TNF receptors (TNF-
                                                                                             RI and TNF-RII) on vascular
                                                                                             endothelium
  Cyclic CNGRCG peptide:                                                                     Strong antitumour effect
     targets tvCD13, a                                                                       Destroys blood vessel function
     receptor present on
                                                                                             Approved as anticancer drug,
     tumour neo-vasculature
                                                                                             but toxicity limits application
                                                                                             to isolated limb perfusion
                                   Resolution: 2.8 Å




MolMed S.p.A. – Italian Stock Market Opportunities Conference, Milan, September 17, 2009                                   16
                                                           NGR-hTNF Phase II trials as single agent

    Optimal safety profile:
       • No cumulative or long-term toxicity observed
       • Side effects essentially consitutional symptoms (chills) limited to infusion time
    3 single arm trials (enrolment completed) in pre-treated patients with
    advanced disease, with 2 administration schedules tested (q3w and q1w):
       •   Colorectal carcinoma (NGR006): overall survival more than doubled with respect to
           data reported for best supportive care
       •   Hepatocellular carcinoma (NGR008): ongoing complete tumour necrosis in a patient
           refractory to sorafenib
       •   Malignant pleural mesothelioma (NGR010): dose intensification may significantly
           prolong disease control duration



                                             Results presented at ASCO 2009




MolMed S.p.A. – Italian Stock Market Opportunities Conference, Milan, September 17, 2009          17
                                  Results in colorectal cancer (Phase II trial NGR006)

Antitumour activity (46 heavily pre-treated                                            Overall survival
pts):
    Schedule: 33 pts q3w, 13 pts q1w                                                         Best supportive care
                                                                                                  Median OS:
    DCR (SD or PR): 39%                                                                            6 months    NGR-hTNF
                                                                                                            Median OS:
    Median PFS = 2.5 months                                                                                13.1 months
    (1.8 months reported for BSC)
                                                                                                                     Median follow-up:
    Median OS = 13.1 months




                                                                          Percent survival
                                                                                                                        22.1 months
    (6 months reported for BSC)                                                                                    16 patients (35%) alive
    Long-term follow-up (Median 22.1 months):
    35% of patients alive




   Overall survival more than doubled
     with respect to data reported                                                                  6
        for best supportive care                                                                              13.1

                                                                                                          Time (months)
Source: ASCO 2009, Abstract 4088 (Poster)
MolMed S.p.A. – Italian Stock Market Opportunities Conference, Milan, September 17, 2009                                                18
                                              Results in liver cancer (Phase II trial NGR008)

Antitumour activity (39 pts):                                               Contrast-enhanced CT-scan (arterial phase)
    Schedule: 27 pts q3w, 12 pts q1w
    DCR: 28% - 1 ongoing CR & 1 PR achieved
    Median PFS = 2.3 months
    (no BSC data available)                                                                             February 2008:
                                                                                                           baseline
    Median OS not yet reached
    (60% at 6 months)
    Top-line results will be presented at ESMO
    2009



                                                                                                          May 2008:
                                                                                                        after 4 cycles
   Ongoing, complete tumour necrosis                                                                    of NGR-hTNF
   in a patient refractory to sorafenib



Source: ASCO 2009, Abstract 15500
MolMed S.p.A. – Italian Stock Market Opportunities Conference, Milan, September 17, 2009                                 19
                                            Results in mesothelioma (Phase II trial NGR010)

Antitumour activity (57 pts):                                                       PFS comparison: q1w vs q3w schedule
    Schedule: 43 pts q3w, 14 pts q1w
    DCR (SD or PR): 46%
                                                                                                       q1w schedule:
    Median PFS = 2.8 months                                                                              6-month PFS rate: 36%
    (vs 1.5 months reported for BSC)                                                                     Median PFS in pts with DC: 9.1 months

    Median Overall Survival = 12.1 months                                                100           q3w schedule:
                                                                                                         6-month PFS rate: 13%
    (vs 9.7 months reported for BSC)                                                                     Median PFS in pts with DC: 4.4 months
                                                                                              80
    Dose intensification leads to a nearly




                                                                           Percent survival
    three-fold PFS at 6 months
                                                                                              60


                                                                                              40               36%

          The dose intensification may                                                        20
                                                                                                               13%
             significantly prolonge
            disease control duration                                                          0
                                                                                                   0    3       6       9       12      15
                                                                                                              Time (months)

Source: ASCO 2009, Abstract 7582 (Poster)
MolMed S.p.A. – Italian Stock Market Opportunities Conference, Milan, September 17, 2009                                                     20
                                        NGR-hTNF Phase II trials in combination therapy


    Favourable safety profile with all combination drugs tested, with no
    overlapping toxicity
    3 single arm trials in pre-treated patients with advanced disease:
       •   + Xelox in colorectal carcinoma (NGR005): enrolment completed, started December
           2007 - Results will be presented at ESMO 2009
       •   + doxorubicin in lung cancer-SCLC (NGR007) – ongoing, started February 2008
       •   + doxorubicin in ovarian carcinoma (NGR012) – ongoing, started November 2008
    1 randomised trial as first-line treatment:
       •   + cisplatin-based regimens (cis-gem or cis-pem) in lung cancer-NSCLC (NGR014) –
           ongoing, started June 2009




MolMed S.p.A. – Italian Stock Market Opportunities Conference, Milan, September 17, 2009     21
                                       Multiple potential applications in cancer therapy

    Novel mechanism of action offers new treatment options:
       •   For refractory patients, pre-treated with anti-angiogenic and chemotherapy regimens
       •   For indications with high unmet need and few therapeutic options (Orphan Drug
           designation in both EU and US for mesothelioma)
    Very favourable toxicity profile as single agent and in combination
    Enhances activity of chemotherapy
    Activity in a variety of solid tumours


     Proven anticancer activity in single agent Phase II trials,
          endorsing the vast applicability of NGR-hTNF




MolMed S.p.A. – Italian Stock Market Opportunities Conference, Milan, September 17, 2009         22
                                                 Unique assets for cancer therapy innovation

MolMed value proposition
                      Only approach enabling HSCT for all patients lacking a fully matched donor
     TK
                      Phase III in high-risk leukaemia started in Italy
                      Project of own industrial production capability and commercialisation to
                      specialised clinical centres
                      Market potential: € 390-420 million expected peak sales1

NGR-hTNF              VTA with unique and broad potential in very different types of solid tumours
                      Efficacy in indications with no treatment options and/or in heavily pre-treated
                      patients
                      Commercialise in Europe, partner with pharma/biotech companies in US & ROW
                      Market potential: € 2.6 billion expected peak sales2




Note: Peak sales in Europe, U.S. and Japan. Indications: for TK acute myeloid leukaemia (AML); for NGR-hTNF colorectal (CRC), liver (HCC) and small-
cell lung cancer (SCLC), and mesothelioma (MPM)
Sources: 1Analyst consensus (Nomura Code, Société Générale); 2Updated company assessment after ESMO 2008

MolMed S.p.A. – Italian Stock Market Opportunities Conference, Milan, September 17, 2009                                                           23
                                                                                  Milestones 2H 2009 and 2010


                Anticipated 2009                                               Anticipated 2010
    TK             Expand Ph III trial (TK008) in Europe                          Expand Ph III trial (TK008) in US
                                                                                  Preliminary Ph III data



                   Start 2 randomised Phase II trials:                            Start of Ph III trial in MPM
                     • in NSCLC + cisplatin                              V        Top line results Ph I trial high dose
                     • in STS + doxorubicin                                       (NGR013) – ASCO 2010
                   Start Ph I trial high doses (NGR013)                  V        Top line results of Ph II trials:
NGR-hTNF
                   Top line results of Ph II trials:
                                                                                    • SCLC + doxo (NGR007) – ESMO 2010
                     • CRC (NGR006) – ASCO 2009                                     • OC + doxo (NGR012) – ESMO 2010
                                                                         V
                                                                                  First results Ph II randomised trial NSCLC
                     • HCC (NGR008) – ESMO 2009                                   + cis-gem/cis-pem (NGR014) - ESMO 2010
                     • MPM (NGR010) – ASCO 2009                          V        Randomisation of Ph II trials +
                   First results of Ph II trial in CRC +                          doxorubicin (indication tbd)
                   Xelox (NGR005) – ESMO 2009


Legenda for NGR-hTNF indications: SCLC = small-cell lung cancer; CRC = colorectal cancer; OC = ovarian cancer; STS = soft
tissue sarcomas; HR-PC = hormone-refractory prostate cancer; HCC = liver cancer; MPM = mesothelioma
MolMed S.p.A. – Italian Stock Market Opportunities Conference, Milan, September 17, 2009                                       24
                                                                                           Shareholders structure

    Public company with strong investors

    Listed on Milan Stock Exchange (MTA, standard segment) since March 5, 2008:
       • Ticker: MLM
       • Ticker Reuters: MLMD.MI
                                                                     Shareholders (April 14, 2009)
       • Ticker Bloomberg: MLM IM
                                                                     Science Park Raf S.p.A.                   Airain Lda
                                                                             21.14%                             21.12%

    Financials:                                                                                                          Fininvest
       • Capital raised at IPO: € 56 million                                                                               S.p.A.
                                                                                                                          17.33%
       • Issued shares: 104,467,808
                                                                          Free float
       • Market cap (September 10, 2009):                                  21.55%                H-Equity
                                                                                                            Delfin S.àr.l.
                                                                                                               8.66%
          € 173 million                                                           Arner Bank S.A. S.àr.l.
                                                                                      2.01%       SICAR
                                                                                                  8.19%




(∗) Source: MolMed Shareholders Meeting 2009
MolMed S.p.A. – Italian Stock Market Opportunities Conference, Milan, September 17, 2009                                         25
                                                                                      Share performance since IPO

 Share performance (price & volumes) from March 5, 2008 to September 10, 2009
                                                                                                                                    2.20
                                                                                                                                    2.00

                                                                                                                                    1.80
    Share price (€)




                                                                                                                                    1.60

                                                                                                                                    1.40


                             MLM                                                                                                    1.20

                             FTSE-MIB
                             BTK (Amex Biotech Index)                                                                               1.00
                             NBI (Nasdaq Biotech Index)

                                                                                                                                    0.80


                      2008   May   Jun   Jul   Aug   Sep   Oct   Nov   Dec   2009   Feb   Mar   Apr   May   Jun   Jul   Aug   Sep

                                                                                                                                    1.5M
    Volumes




                                                                                                                                    1.0M


                                                                                                                                    0.5M




                      Issued shares: 104,467,808
                      Market cap (September 15, 2009): € 172 million
MolMed S.p.A. – Italian Stock Market Opportunities Conference, Milan, September 17, 2009                                                   26
                                                                                                            Financials

MolMed financials (€ thousand)

                                                       FY 2006            FY 2007          FY 2008    1H 2008    1H 2009


Revenues & other income                                    2,725             3,814           3,963        912       2,879

Operating costs                                        (13,563)          (16,763)          (23,073)   (11,508)    (11,054)

Loss for the period                                    (10,697)          (12,696)          (19,110)    (9,873)     (7,788)



Net financial position                                     8,426             5,666          35,281      44,061     26,935

        Strong net financial position due to IPO proceeds and careful cash management
        Increase in revenues in 1H09 thanks to growth of services provided to third parties
        and to receipt of tax credit on R&D expenses
        In 2009 MolMed planned a tight control on cash burn, to be kept in line with 2008
        According to current estimate, MolMed has sufficient cash at least until end 2010

MolMed S.p.A. – Italian Stock Market Opportunities Conference, Milan, September 17, 2009                                   27
                                                                                           Forthcoming events 2009


 Financial calendar (∗)
Financial calendar (∗):
    November 9                            Financial report for Q3 2009



 Upcoming presentations

    September 20-24                       ESMO annual meeting, Berlin:
                                          NGR-hTNF clinical development update
    November 2-4                          Bio Europe, Wien:
                                          updated company presentation




(∗): Reports, presentations and press releases related to the past events of the financial calendar can be
    downloaded from MolMed’s website

MolMed S.p.A. – Italian Stock Market Opportunities Conference, Milan, September 17, 2009                         28
                                                                              Strong position to create value

    Unique investigational therapies that generate major value
    € 27 million cash
    Flexible business strategy: independently and/or with partners
    Progress in clinical development providing near term value inflection points
    Option right from San Raffaele Foundation (opportunity to feed pipeline)

                                                                 Late-stage
                                                                  pipeline
                                                                                              Leader in
                                    Proven
                                                                                           oncology clinical
                                  innovation
                                                                                            development
                                                                                                                Financial
  Team-driven
                                                                                                                strength
    culture
                                                                                                               due to IPO




MolMed S.p.A. – Italian Stock Market Opportunities Conference, Milan, September 17, 2009                                    29
Contact:
Holger Neecke                                                                               an integrated
Director Business Development & Investor Relations                                               strategy
MolMed S.p.A.
Via Olgettina, 58                                                                          to cure cancer
20132 Milan, Italy
phone: +39 02212771
fax: +39 0221277.325
e-mail: investor.relations@molmed.com




      THANK YOU VERY MUCH
       FOR YOUR ATTENTION

MolMed S.p.A. – Italian Stock Market Opportunities Conference, Milan, September 17, 2009

				
DOCUMENT INFO